Skip to content

Safety overdose test of test food

Safety overdose study of taxifolin-containing food -Open-label study- - Safety overdose study of taxifolin-containing food

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049810
Enrollment
20
Registered
2023-02-03
Start date
2023-02-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adult

Interventions

Sponsors

Miura Clinic, Medical Corporation Kanonkai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Subjects of men and women aged 20 to 64 (2) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing

Exclusion criteria

Exclusion criteria: (1) Subjects with heart, liver, and kidney diseases (including complications of other diseases) (2) Subjects with a history of cardiovascular diseases (3) Subjects with diabetes (4) Subjects with diseases currently being treated (5) Subjects who are allergic to foods and drugs (6) Subjects with anemia symptoms (7) Female subjects wishing to become pregnant while participationg in this study, pregnant (including those who may be pregnant) or lactating female subjects (8) Subjects who are going to the hospital for some illness or are being treated with drugs and Chinese medicine (as needed) (9) Subjects who play intense sports and subjects who are on a diet (10) Subjects with extremely irregular eating habits (11) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (12) Subjects who drink more than 60g of average daily pure alcohol (13) Subjects who smoke an average of 21 or more cigarettes a day (14) Subjects who are participating in or will participate in other clinical trials at the start of this study. (15) Other subjects judged by the investigator or the investigator to be inappropriate for the examination

Design outcomes

Primary

MeasureTime frame
Adverse event Physical examination Laboratory test values

Countries

Japan

Contacts

Public ContactMakoto Terashima

Oneness Support Co., Ltd. Clinical Trial Division

mterashima@oneness-sup.co.jp06-4801-8917

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026